![woman smiling -Alto Neuroscience - hero image](https://altoneuroscience.com/wp-content/uploads/2024/09/woman-smiling-alto_neuroscience-hero.jpg)
The future of psychiatry is precision
We develop biology-driven medicines for neuropsychiatric conditions so that patients can get better faster.
![brain line image](https://altoneuroscience.com/wp-content/uploads/2024/09/brain-line-image-alto_neuroscience-home.png)
Measuring brain biology to drive clinical success
Our approach enables us to predict clinical response and identify patients who are most likely to benefit from our drug candidates.
![wavy lines - background](https://altoneuroscience.com/wp-content/uploads/2024/09/Wavy_Lines-background-image-GreyPinkBlue.png)
![](https://altoneuroscience.com/wp-content/uploads/2024/10/Wavy_Lines-background-image-GreyPinkBlue-mobile.png)
Harnessing deep neurobiological insights to develop novel medicines
Built on 15 years of our field-leading neurobiology research, our clinical-stage drug candidates are designed to target core brain processes in people suffering from a range of neuropsychiatric conditions, with an initial focus on major depressive disorder, bipolar depression, and schizophrenia.
![Scientist with tablet -alto neuroscience](https://altoneuroscience.com/wp-content/uploads/2024/09/Scientist_with_tablet-alto_neuroscience.png)
![photos of employees - Alto Neuroscience](https://altoneuroscience.com/wp-content/uploads/2024/09/Photo_Grouping-leading_innovation_callout-homepage.png)
Driving innovation in psychiatry
We’re disrupting today’s trial-and-error approach to treating neuropsychiatric conditions. Our team leverages deep expertise in CNS drug development and commercialization to offer patients alternative treatment options for their conditions.